Germ Cell Tumors

In another major effort from ASCO and its members, guidelines and recommendations have been release for Germ Cell Tumors during this shortage of essential chemotherapeutic agents such as cisplatin and carboplatin. @ASCO @ASCOPres @FLASCO_ORG https://t.co/pDk5hF3e3u (@edgardo_ny)

Nice message for active surveillance and shared decision with patients with stage 1 germ cell cancers (@drcmassard)

Maintenance oral etoposide after high-dose chemotherapy (HDCT) for patients with relapsed metastatic germ-cell tumors. #BeyondTheAbstract with @nabiladra @IUCancerCenter. #ReadNow on UroToday > https://t.co/zHoxV7kSd6 #TesticularCancer @FadiTaza @RafatAbonour @DrM_AbuZaid (@urotoday)

Siamak Daneshmand, MD, on Primary Retroperitoneal Lymph Node Dissection for Low-Volume Metastatic Seminoma https://t.co/w11rcGRwMZ @siadaneshmand @KeckMedUSC @KECKSchool_USC @uscnorris #uscurology (@USC_Urology)

🌟 📢 New study findings shed light on the need for surgical resection in patients with residual nonretroperitoneal (non-RP) disease after chemotherapy for nonseminomatous germ cell tumors: @ASCO #ASCO23 @OncoAlert @GTumors ✅ Lack of teratoma in primary tumor doesn't rule out… https://t.co/IV1xAKw5ob (@nataliagandur)

Molecular drivers of organotropism and cisplatin resistance in #GermCell tumors. Presentation by @AdityaBagrodia @UCSDHealth. #ASCO23 written coverage by @zklaassen_md @GACancerCenter > https://t.co/quYVtK1lA2 @ASCO (@urotoday)

Primary RPLND in #seminoma stage IIA-IIC ≤3cm: combined results of the #SWENOTECA (Swedish Norwegian Testicular Cancer Group) and Cologne. Presented by @torgrimtandstad @StOlavshospital. #ASCO23 written covrage by @zklaassen_md @GACancerCenter > https://t.co/2d1x2B3wbz @ASCO (@urotoday)

#ASCO23 Discussant: Germinating data for #GermCell tumors. Presentation by @DrBenTran @PeterMacCC. Written coverage by @zklaassen_md @GACancerCenter on UroToday > https://t.co/O6Y5LnZCDj @ASCO (@urotoday)

GI is the new lymphoma/seminoma. Esophageal is the last holdout and xrt is one drug or io combo away from being kicked out of that. (@lemmiwenks)

🧬 @AdityaBagrodia examining molecular landscape in platinum-resistant disease. 🔪 @torgrimtandstad presenting data on primary RPLND in seminoma, accompanying growing evidence supporting the practice in selected patients. @OncoAlert @ASCO #ASCO23 #testicularcancer (2/2) (@ciaraconduit)

5) Further exploration of biomarker work in testicular germ cell tumor #tscsm. How can we predict chemo response? But also how can we limit morbidity and mortality after cure? Larger role for RPLND? - @BGarmezy #ASCO23 #ASCO2023 @SarahCannonDocs (@OncLive)

Dr. Tandstad presents data showing RPLND in stage IIA/IIB testicular germ cell tumors can potentially spare toxicity from chemotherapy and improve non testicular cancer mortality. It’s important to remember the lives of our patients after cancer. #ASCO23 #ASCO2023 - @BGarmezy (@OncLive)

@LuciaNappi4 presents further data using miR371 to detect relapse in stage 1 testicular germ cell tumors. Excellent specificity. SWOG S1823 ongoing and will hopefully show this is ready for use in our clinics. #ASCO23 #ASCO2023 #tscsm - @BGarmezy @SarahCannonDocs (@OncLive)

Sam Funt from ⁦@MSKCancerCenter⁩ describes an IO/IO study in refractory #germcell tumors. Minimal activity and novel mechanisms are needed. ⁦@DrDarrenFeldman⁩ (@Uromigos)

High-dose chemotherapy is the recommended third line therapy and second line therapy for higher risk germ cell cancer.... ⭕️ Should it be second line for all patients? TIGER will answer this question @ChrisSweens1 @DrDarrenFeldman @tompowles1 @Silke_Gillessen @Uromigos @ASCO… https://t.co/6nMdeGTWfm (@DrYukselUrun)

Most non-seminomatous germ cell cancer patients have good or intermediate prognosis! @Silke_Gillessen @ASCO #ASCO23 @OncoAlert (@DrYukselUrun)

Should transplant be second line in advanced non-seminoma? Very nice debate to start Day 2 of #ASCO23 @ekwaller eloquently highlights the @WinshipAtEmory experience #TIGER trial results are very much awaited (@BasselNazha)

El seminoma puede hacer eso también (@JavierMauTo)

De neo de testiculoo supongo que seminoma por frequencia pero no descartaria el sarcoma y el retroperitoneo bien llenito también (@Flint_Science)

Seminoma (@Enchiladasdey14)

Either oligodendrogioma or dysgerminoma (@ahmed_zeni)

Oligodendroglioma, Seminoma (@Frost_Bel)

Maintenance oral etoposide after high-dose chemotherapy (HDCT) for patients with relapsed metastatic germ-cell tumors. #BeyondTheAbstract with @nabiladra @IUCancerCenter. #ReadNow on UroToday > https://t.co/zHoxV7kSd6 #TesticularCancer @FadiTaza @RafatAbonour @DrM_AbuZaid (@urotoday)

Excellent talks by @siadaneshmand on the modern mgmnt of #bladdercancer and stage II seminoma, and @Hoomandjaladat on the surgery for advanced #RCC https://t.co/tq6axo01aq (@alirezaghoreifi)

1/2 Differentials of pelvic mass in a child - ⏺ Germ cell tumor ( ovary/sacrococcygeal) ⏺️ Rhabdomyosarcoma (genito urinary) ⏺️ Neuroblastoma ⏺️Ewings sarcoma ⏺️lymphoma ⏺️ Desmoplastic small round cell tumor ⏺️ Chondrosarcoma (@Satyayadav__)

1) Vaginal/Bladder Rhabdomyosarcoma 2) Germ cell tumor 3) Paraspinal mass - Neuroblastoma (@TanV_67)

Discussion across GU malignancies to start day at #GU23 Biomarkers of response to Enfortumab Vedotin in UC, cabo/nivo in RCC, updated analysis of nivo/ipi of CRPC - high TMB not predictive of benefit and new clinical risk stratification for relapse in stage 1 seminoma @OncLive (@BradMcG04)

💫TP53 Alterations➡ Poor Survival in Pts w/ Primary Mediastinal Nonseminoma Germ Cell Tumors @AndreaNecchi Dr. Christian K Kollmannsberger of @UBCmedicine @UBC @OncoAlert @TCSociety @Uroweb Dr. Alexander W. Wyatt Dr. Giovanna Cataldo Dr. Jack V.W. Bacon https://t.co/wNYuofTWiG (@nataliagandur)

)1. Metastatic adenocarcinoma, from prostate- NKX3.1 or from GIT CDX2 or SATB2 IHC 2.Metastatic germ cell tumor? OCT4 IHC (@CPremalata)

Seminoma & Embryonal Carcinoma in Transition Part 1: abrupt - note differences in cytoplasm and nuclear features & contrast in CD30 #IHC labeling #testicularcancer #gupath @TestesCancer (@rovingatuscap)

Activity of PD1/PDL1 inhibitors is quite low in platinum-refractory germ cell tumors. Vaccines and CAR-T cells may be the right direction for immunotherapy in these poor-prognosis tumors. Data from the ph1 CLDN6 CART-T and CARVac mRNA vaccine from @BioNTech_Group at #AACR2022 (@y_loriot)

How often do you find scattered glypican 3 cells in pure seminomas? (@jackjacob)

Testicular Seminoma #IHC upper R = OCT4(+) [nuclear] lower L = CD117 {c-kit} (+) [membranous] lower R = pancytokeratin AE1/AE3 🚨pancytokeratin (+) has linear or peri-nuclear hof pattern; not uncommon in seminoma & does not indicate carcinomatous transformation #gupath (@rovingatuscap)

Elderly male, testicular tumor. Seminoma (IHC: OCT4) was weird enough, separate mid-spermatic cord tumor nodule made the case remarkable. Vasitis nodosa. #gupath @Williamson_SR @LiangChengMD @GladellPaner @rovingatuscap @daniel_berney (@AkgulMd)

"Identification of 22 susceptibility loci associated with testicular germ cell tumors." ➡CHEK2 is the only moderate penetrance #gene in which PVs have been associated with risk of TGCT. @NicoleKuderer @Dr_Ivanoncologo @gary_lyman https://t.co/jK5PC2gxhT (@Kristel_GT)

Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial https://t.co/Np57Bz7aTv via @rightrelevance thanks @viveksubbiah (@ChocolatiereP)

NGS identified a case of a RET amplification as a potential basis of sensitivity to sunitinib in a patient with refractory germ cell tumor. https://t.co/SooG7mXFzU (@VivekSubbiah)

BEP for germ cell tumors ICI for MSI-H tumors (@MarcelMassoud07)

7/n within FGF-23-driven: a. tumor induced osteomalacia (TIO) or oncogenic osteomalacia, commonly germ cell line tumors but other malignancies can do it. b. Rare cases of ferric carboxymaltose-induced ⬆️ in FGF-23 https://t.co/RBsdGV5Ahw (@VelezNephHepato)

Our latest: RAS/MAPK Alterations Are Associated with KIT Mutations in Germ-cell Tumors and May Have Therapeutic Implications https://t.co/GHBSAdqC5S @MLadanyi @DrDarrenFeldman @jamalbenhamida @CDebyaniPhD (@DouglasMataMD)